FNP NURS6203
Advanced Pharmacology
4.0 Credits
Final Exam Review (Qns & Ans)
2025
©2025
, 1.
Case: A 65‑year‑old patient with advanced heart failure is prescribed a
novel drug. During dosing studies, you note that small increases in dose
produce disproportionately high plasma concentrations.
Question: Which of the following is most likely responsible for this
non‑linear pharmacokinetic profile?
A. Reduced intestinal absorption
B. Saturation of hepatic metabolic enzymes
C. Enhanced renal clearance
D. Increased plasma protein binding
Correct ANS: B. Saturation of hepatic metabolic enzymes
Rationale: Non‑linear (or saturable) pharmacokinetics often occur
when hepatic metabolic enzymes (commonly cytochrome P450 enzymes)
reach capacity. This saturation causes disproportionate increases in
plasma drug levels as doses rise.
---
2.
Case: A 50‑year‑old patient with metastatic cancer is prescribed a new
chemotherapeutic agent that functions by intercalating into DNA and
inhibiting topoisomerase II.
Question: What is the primary outcome of this mechanism in tumor
cells?
A. Enhanced repair of DNA lesions
B. Induction of double‑stranded DNA breaks leading to apoptosis
C. Stimulation of protein synthesis
D. Increased transcription of survival genes
Correct ANS: B. Induction of double‑stranded DNA breaks leading to
apoptosis
Rationale: DNA intercalators inhibit topoisomerase II activity, leading
to double‑stranded breaks in DNA. The resulting damage triggers
apoptotic pathways, which are desirable for eliminating rapidly dividing
tumor cells.
©2025
,---
3.
Case: A 45‑year‑old patient with chronic pain is being considered for a
novel opioid that selectively activates delta opioid receptors.
Question: Which potential advantage is most associated with delta
receptor agonism compared to traditional mu‑opioid agonists?
A. Enhanced euphoria and increased misuse potential
B. Reduced risk of respiratory depression and constipation
C. Increased incidence of dependence and tolerance
D. Lower intrinsic analgesic potency
Correct ANS: B. Reduced risk of respiratory depression and
constipation
Rationale: Delta receptor agonists are being investigated for
maintaining analgesic efficacy while minimizing common mu‑opioid side
effects such as respiratory depression, gastrointestinal dysmotility
(constipation), and euphoria.
---
4.
Case: A 50‑year‑old diabetic patient is prescribed a glucagon‑like
peptide‑1 (GLP‑1) receptor agonist.
Question: Which of the following mechanisms best explains the drug’s
glucose‑lowering effect?
A. Direct stimulation of insulin secretion regardless of blood glucose
levels
B. Delayed gastric emptying and promotion of satiety
C. Inhibition of renal glucose reabsorption
D. Direct blockade of glucagon receptors
Correct ANS: B. Delayed gastric emptying and promotion of satiety
Rationale: GLP‑1 receptor agonists lower blood glucose by promoting
glucose‑dependent insulin secretion, delaying gastric emptying (thus
slowing glucose absorption) and enhancing satiety, which may also lead
©2025
, to weight loss.
---
5.
Case: A 30‑year‑old female undergoes pharmacogenomic testing prior
to initiating therapy. The test reveals that she is an ultra‑rapid
metabolizer of CYP2D6.
Question: How might this phenotype affect her response to
medications?
A. She may require higher doses of prodrugs that require CYP2D6
activation.
B. She will have prolonged drug effects due to decreased metabolism.
C. She will be less likely to experience drug interactions.
D. She requires lower doses of medications metabolized by CYP2D6.
Correct ANS: A. She may require higher doses of prodrugs that
require CYP2D6 activation.
Rationale: Ultra‑rapid metabolizers convert certain prodrugs to their
active forms very efficiently, sometimes necessitating a higher dose to
achieve therapeutic effects. Conversely, drugs that are inactivated by
CYP2D6 may be cleared faster.
---
6.
Case: A 68‑year‑old patient with non‑valvular atrial fibrillation is
started on a novel direct Factor Xa inhibitor.
Question: Which feature provides a significant clinical advantage over
traditional warfarin therapy?
A. A wide therapeutic index with minimal dietary interactions and no
need for routine INR monitoring
B. Complete elimination of bleeding risk
C. Requirement for frequent dose adjustments based on vitamin K intake
D. Predictable protein binding that necessitates monitoring of serum
levels
©2025
Advanced Pharmacology
4.0 Credits
Final Exam Review (Qns & Ans)
2025
©2025
, 1.
Case: A 65‑year‑old patient with advanced heart failure is prescribed a
novel drug. During dosing studies, you note that small increases in dose
produce disproportionately high plasma concentrations.
Question: Which of the following is most likely responsible for this
non‑linear pharmacokinetic profile?
A. Reduced intestinal absorption
B. Saturation of hepatic metabolic enzymes
C. Enhanced renal clearance
D. Increased plasma protein binding
Correct ANS: B. Saturation of hepatic metabolic enzymes
Rationale: Non‑linear (or saturable) pharmacokinetics often occur
when hepatic metabolic enzymes (commonly cytochrome P450 enzymes)
reach capacity. This saturation causes disproportionate increases in
plasma drug levels as doses rise.
---
2.
Case: A 50‑year‑old patient with metastatic cancer is prescribed a new
chemotherapeutic agent that functions by intercalating into DNA and
inhibiting topoisomerase II.
Question: What is the primary outcome of this mechanism in tumor
cells?
A. Enhanced repair of DNA lesions
B. Induction of double‑stranded DNA breaks leading to apoptosis
C. Stimulation of protein synthesis
D. Increased transcription of survival genes
Correct ANS: B. Induction of double‑stranded DNA breaks leading to
apoptosis
Rationale: DNA intercalators inhibit topoisomerase II activity, leading
to double‑stranded breaks in DNA. The resulting damage triggers
apoptotic pathways, which are desirable for eliminating rapidly dividing
tumor cells.
©2025
,---
3.
Case: A 45‑year‑old patient with chronic pain is being considered for a
novel opioid that selectively activates delta opioid receptors.
Question: Which potential advantage is most associated with delta
receptor agonism compared to traditional mu‑opioid agonists?
A. Enhanced euphoria and increased misuse potential
B. Reduced risk of respiratory depression and constipation
C. Increased incidence of dependence and tolerance
D. Lower intrinsic analgesic potency
Correct ANS: B. Reduced risk of respiratory depression and
constipation
Rationale: Delta receptor agonists are being investigated for
maintaining analgesic efficacy while minimizing common mu‑opioid side
effects such as respiratory depression, gastrointestinal dysmotility
(constipation), and euphoria.
---
4.
Case: A 50‑year‑old diabetic patient is prescribed a glucagon‑like
peptide‑1 (GLP‑1) receptor agonist.
Question: Which of the following mechanisms best explains the drug’s
glucose‑lowering effect?
A. Direct stimulation of insulin secretion regardless of blood glucose
levels
B. Delayed gastric emptying and promotion of satiety
C. Inhibition of renal glucose reabsorption
D. Direct blockade of glucagon receptors
Correct ANS: B. Delayed gastric emptying and promotion of satiety
Rationale: GLP‑1 receptor agonists lower blood glucose by promoting
glucose‑dependent insulin secretion, delaying gastric emptying (thus
slowing glucose absorption) and enhancing satiety, which may also lead
©2025
, to weight loss.
---
5.
Case: A 30‑year‑old female undergoes pharmacogenomic testing prior
to initiating therapy. The test reveals that she is an ultra‑rapid
metabolizer of CYP2D6.
Question: How might this phenotype affect her response to
medications?
A. She may require higher doses of prodrugs that require CYP2D6
activation.
B. She will have prolonged drug effects due to decreased metabolism.
C. She will be less likely to experience drug interactions.
D. She requires lower doses of medications metabolized by CYP2D6.
Correct ANS: A. She may require higher doses of prodrugs that
require CYP2D6 activation.
Rationale: Ultra‑rapid metabolizers convert certain prodrugs to their
active forms very efficiently, sometimes necessitating a higher dose to
achieve therapeutic effects. Conversely, drugs that are inactivated by
CYP2D6 may be cleared faster.
---
6.
Case: A 68‑year‑old patient with non‑valvular atrial fibrillation is
started on a novel direct Factor Xa inhibitor.
Question: Which feature provides a significant clinical advantage over
traditional warfarin therapy?
A. A wide therapeutic index with minimal dietary interactions and no
need for routine INR monitoring
B. Complete elimination of bleeding risk
C. Requirement for frequent dose adjustments based on vitamin K intake
D. Predictable protein binding that necessitates monitoring of serum
levels
©2025
